Alloplex Biotherapeutics, LLC is a Boston-based cellular therapeutics company founded in 2016. Led by scientific founder Dr. Frank Borriello, Alloplex has developed a highly-differentiated, non-engineered cellular therapy platform with the potential to treat various types of cancer. Their proprietary SUPLEXA cells have shown promising results in a Phase 1 clinical trial, demonstrating both clinical efficacy and a reassuring safety profile. By reprogramming rather than genetically engineering cells, Alloplex's SUPLEXA therapeutic cells exhibit potent anti-tumor activity without the complications associated with genetic manipulation. With a focus on simplicity, reproducibility, and high yields, Alloplex aims to provide a robust and effective cellular therapy option for end-stage metastatic cancer patients.
Generated from the website